Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Corticosteroids for Guillain-Barré syndrome.

R A C Hughes1, A V Swan, R van Koningsveld

  • 1King's College London School of Medicine, Department of Clinical Neuroscience, 2nd Floor, Hodgkin Building, Guy's Hospital, London, UK, SE1 1UL. richard.a.hughes@kcl.ac.uk

The Cochrane Database of Systematic Reviews
|April 21, 2006
PubMed
Summary

Corticosteroids do not significantly improve recovery for Guillain-Barré syndrome (GBS). Oral corticosteroids may slow recovery, while intravenous treatments show no significant benefit or harm, necessitating further research for effective GBS treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CIDP With and Without Monoclonal Gammopathy of Undetermined Significance (MGUS): Comparison of Clinical Phenotype, Diagnostic Features, and Treatment Response.

Journal of the peripheral nervous system : JPNS·2026
Same author

Guillain-Barré Syndrome Disability Scale.

Journal of the peripheral nervous system : JPNS·2025
Same author

Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudy.

The Journal of dermatology·2025
Same author

Knowledge gaps in diagnosing chronic polyneuropathy: Review of national guidelines.

Journal of the peripheral nervous system : JPNS·2024
Same author

Reply to the Letter to the Editor "Do corticosteroids aggravate pure motor chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)?" by Kokubun N. et al.

Journal of the peripheral nervous system : JPNS·2024
Same author

Oral ribose supplementation in dystroglycanopathy: A single case study.

JIMD reports·2024

Area of Science:

  • Neurology
  • Clinical Trials
  • Immunology

Background:

  • Guillain-Barré syndrome (GBS) involves peripheral nerve inflammation, suggesting potential benefit from corticosteroids.
  • The study investigates corticosteroids for GBS recovery and long-term morbidity.

Purpose of the Study:

  • To evaluate the efficacy of corticosteroids in accelerating recovery from Guillain-Barré syndrome.
  • To assess the impact of corticosteroids on reducing long-term disability in GBS patients.

Main Methods:

  • Systematic review of quasi-randomised or randomised controlled trials of corticosteroids in GBS.
  • Inclusion of trials involving patients of all ages and GBS severity.
  • Primary outcome: change in disability grade at four weeks; secondary outcomes: recovery time, mortality, and adverse events.

Related Experiment Videos

Main Results:

  • No significant difference in disability grade between corticosteroid and non-corticosteroid groups overall.
  • Oral corticosteroids were associated with significantly less improvement in disability at four weeks.
  • Intravenous corticosteroids showed a non-significant trend towards improvement; no significant differences in secondary outcomes were observed.

Conclusions:

  • Limited evidence suggests oral corticosteroids may significantly slow GBS recovery.
  • Intravenous methylprednisolone alone offers no significant benefit or harm in GBS.
  • Combination therapy with IVIg and methylprednisolone may hasten recovery but doesn't alter long-term outcomes; further research is needed.